Clostridium difficile causes colitis following antibiotic-mediated perturbation of the intestinal microbiota. C. difficile causes over 500,000 infections per year, with an estimated 15,000 deaths annually in the United States. Ingestion of infectious spores from contaminated environments represents the major route by which this infection is acquired. Very little is known about interactions between C. difficile and the normal intestinal microbiota or with the host innate immune system. Our laboratory has investigated C. difficile infection in antibiotic treated mice and demonstrated that stimulating TLR-5 with bacterial flagellin or TLR7/8 with resiquimod markedly enhances resistance to C. difficile infection. We have also demonstrated that a single dose of clindamycin results in prolonged susceptibility to C. difficile infection. The goal of this project is to characterize innate immune defenses, includig those induced by the commensal microbial flora, in protection against C. difficile infection.
The first aim i s to characterize the mechanism by which stimulation of TLR5 by flagellin or TLR7/8 by resiquimod enhances resistance to C. difficile infection. We will investigate the role IL22, the arl hydrocarbon receptor and primary and secondary bile salts in TLR-mediated defense against C. difficile infection.
The second aim i s to determine whether intestinal dendritic cells or inflammatory monocytes contribute to resistance to C. difficile infection. We will use CCR2-reporter and CCR2-depletor mice that were generated in our laboratory to determine the impact of inflammatory monocytes on the pathogenesis of C. difficile colitis.
The third aim i s to determine the effect of different antibiotic treatments on the composition of the intestinal microbial flora. We will use the Roche 454 massively parallel pyrosequencing platform to determine microbial complexity in the GI tract, and to correlate changes in the flora with susceptibility to C. difficile infection. Mice will be reconstituted with fractionated intestinal microbiota and resistance to C. difficile infection will be measured. These studies will identify microbial populations that inhibit germination and/or vegetative growth of C. difficile. Our ultimate goal is to identify the in vivo mechanisms protecting the host from C. difficile infection and to discover practicable approaches, such as selective TLR or cytokine receptor stimulation or microbiota manipulation, to re-induce these mechanisms in vulnerable patients.

Public Health Relevance

Colitis caused by Clostridium difficile is a major complication of antibiotic treatment. Antibiotics destroy normal commensal bacteria in the intestine and thus enable C. difficile to cause disease. The only preventive strategies are to avoid antibiotic use or contact with C. difficile. Our studies will identify immune mechanisms that prevent the development of C. difficile colitis in vulnerable patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI095706-03
Application #
8683090
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Ranallo, Ryan
Project Start
2012-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Westblade, Lars F; van Belkum, Alex; Grundhoff, Adam et al. (2016) Role of Clinicogenomics in Infectious Disease Diagnostics and Public Health Microbiology. J Clin Microbiol 54:1686-93
Lewis, Brittany B; Carter, Rebecca A; Pamer, Eric G (2016) Bile acid sensitivity and in vivo virulence of clinical Clostridium difficile isolates. Anaerobe 41:32-36
Abt, Michael C; Buffie, Charlie G; Sušac, Bože et al. (2016) TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus. Sci Transl Med 8:327ra25
Abt, Michael C; McKenney, Peter T; Pamer, Eric G (2016) Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol 14:609-20
Pamer, Eric G (2016) Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352:535-8
Becattini, Simone; Taur, Ying; Pamer, Eric G (2016) Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol Med 22:458-78
McKenney, Peter T; Pamer, Eric G (2015) From Hype to Hope: The Gut Microbiota in Enteric Infectious Disease. Cell 163:1326-32
Buffie, Charlie G; Bucci, Vanni; Stein, Richard R et al. (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205-8
Abt, Michael C; Lewis, Brittany B; Caballero, Silvia et al. (2015) Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection. Cell Host Microbe 18:27-37
Lewis, Brittany B; Buffie, Charlie G; Carter, Rebecca A et al. (2015) Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. J Infect Dis 212:1656-65

Showing the most recent 10 out of 26 publications